Zanzalitinib for Advanced Prostate Cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called zanzalitinib in men whose prostate cancer has spread and stopped responding to standard hormone treatments. The drug works differently than previous treatments and may help slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic castration-resistant prostate cancer (cancer that has spread and no longer responds to hormone therapy)
- You have received at least one prior hormone-blocking therapy (like abiraterone or enzalutamide)
- Your cancer is visible on CT scans, bone scans, or soft tissue imaging
- Your blood counts and organ function are adequate (recent lab work within 2 weeks)
- You are able to walk and care for yourself most of the day (Karnofsky score ≥60%)
- You have recovered from side effects of previous cancer treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs for men with advanced prostate cancer that has stopped responding to hormone therapy. The drugs are cabozantinib (a pill that may slow cancer growth) and a radioactive therapy that targets prostate cancer cells (177Lu-PSMA-617). The goal is to see if this combination is safe and effective.
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
This trial tests a drug called zanzalintinib for people with advanced thyroid cancer that has spread nearby. The goal is to see if taking this pill before surgery can shrink the tumor and make it easier to remove.
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
This study tests a new drug called zanzalintinib in men with advanced prostate cancer (metastatic castration-resistant prostate cancer) who have already received Pluvicto treatment. The goal is to see if this drug can help slow or stop cancer growth when other hormone therapies are no longer working.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.